- AI-screener
- Securities US
- Sanofi
Sanofi
$49.76
$0.26
0.53%
5 Jun 20:00
$45.80
$60.12
52 weeks low/high
Technical analysis
- Trend ClassTurning down
- Trend PowerSlow trend
- PatternSymmetrical triangle
- EMA-20Bearish reversal2025-05-30 the price crossed down the moving average line and formed a short-term downside trend.
- EMA-50Bearish reversal2025-05-22 the price crossed down the moving average line and formed a short-term downside trend.
- EMA-100Bearish reversal2025-05-06 the price crossed down the moving average line and formed a short-term downside trend.
- StochasticBearishThe stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: signal line crossed the middle level.
- RSIBearish recoveryRSI indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: exit from the overbought zone.
- MACDBearish recoveryOscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: main and signal line crossing.
- Candle pattern typeDojiIs formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.Date of signal:
Prices and risks
Price
| Change | Change by industry | Min. | Max. | Volume | |
|---|---|---|---|---|---|
| Yesterday | -0.53% | 0.68% | $49.51 | $50.09 | 52.63M |
| Week | 0.40% | 1.11% | $48.59 | $50.09 | 420.54M |
| Month | -6.87% | 3.30% | $48.59 | $54.75 | 1.76B |
| 3 Months | -16.73% | 0.82% | $47.70 | $60.12 | 5.87B |
| 6 Months | 2.16% | 11.07% | $45.80 | $60.12 | 10.88B |
| Year | 0.02% | 0.64% | $45.80 | $60.12 | 19.82B |
| 3 years | -6.96% | 70.45% | $36.91 | $60.12 | 50.62B |
| 5 years | -0.86% | 94.92% | $36.91 | $60.12 | 75.68B |
| All time | 86.69% | 75.81% | $23.87 | $58.97 | 69.54B |
Volatility
| SNY | By industry | |
|---|---|---|
| Yesterday | 8.52% | 1.28% |
| Week | 1.36% | 7.29% |
| Month | 7.92% | 10.86% |
| 3 Months | 11.62% | 20.88% |
| 6 Months | 15.03% | 29.79% |
| Year | 25.26% | 39.37% |
| 3 years | 45.37% | 85.40% |
| 5 years | 54.14% | 115.71% |
| All time | — | — |
- Sortino
- -0.02
- Sharpe
- -0.02
- Sterling
- -0.02
- Liquidity index
- 6.43
- Alpha
- 0.00006
- Beta
- 0.37
Fundamental analysis
Indicators for the last quarter and their dynamics for 5 quarters
Ratios
Valuation
Debts
Efficiency
Other ratios
Revenue
Financials
Growth
Assets
Debts
News
About
$122.17B
Capitalization
2.46B
Shares outstanding
Health Care
Sector
Pharmaceuticals
Industry
US80105N1054
ISIN
100
Lot size
Mr. Paul Hudson
CEO
Website
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.